Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2022-06-21 Regulatory Filings
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Regulatory Filings Classification · 85% confidence The document is a press release dated June 21, 2022, announcing the presentation of clinical results (95% vein occlusion rate) by a doctor using Theraclion's SONOVEIN® technology at the Swiss Vein Days 2022 conference. This is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a presentation (IP) or a transcript (CT). It is an announcement of scientific/clinical data being shared externally, which often falls under general investor relations or news releases. Since it is a specific announcement about clinical data/results presented at a medical event, and it doesn't fit the definitions for ER, IR, or AR, the most appropriate category is the general Regulatory Filings (RNS) as a fallback for specific news announcements, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is a summary *about* the presentation. Given the context of sharing clinical outcomes and scientific validation, and lacking a better fit among the specific financial/corporate action codes, RNS (Regulatory Filings/General Announcement) is the safest classification, although it strongly resembles an Investor Presentation summary. However, since it is a press release announcing results presented elsewhere, RNS is used as the general announcement category.
2022-06-21 English
Informations privilégiées / Communiqué sur comptes, résultats
Regulatory Filings Classification · 95% confidence The document is a press release from THERACLION dated June 21, 2022, announcing the presentation of clinical results (95% occlusion rate for vein treatment using SONOVEIN® technology) by Dr. Stalnikiewicz at the Swiss Vein Days 2022 conference. This content focuses on clinical data presentation and company updates regarding technology validation, which aligns best with an Investor Presentation (IP) or a general announcement. Since it is a formal press release detailing specific clinical outcomes and management commentary, it is not a full financial report (10-K or IR), nor is it a simple earnings release (ER) or a dividend notice (DIV). It functions as an update to investors about technological progress and validation, making 'Investor Presentation' (IP) the most suitable category, even though it is presented as a news release rather than a slide deck, as it conveys strategic and performance information to the investment community. Given the context of presenting specific clinical results to a scientific audience and then highlighting the significance to investors, IP is appropriate. It is not a Report Publication Announcement (RPA) because it is the content itself, not just a notice that content exists.
2022-06-21 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated June 13th, 2022, announcing that Theraclion's technology will be featured at the Annual Scientific Meeting of the Society of Interventional Radiology (SIR) on June 15th. It details the presentation topic and speakers. This is not a formal regulatory filing like a 10-K or IR, nor is it a transcript of a call or a formal report itself. It is an announcement related to company activity and scientific presentation, which fits best under general Investor Relations or Regulatory/News announcements. Since it is a specific announcement about a presentation at an industry meeting, and not a formal shareholder meeting (AGM-R) or a general regulatory filing (RNS), it is best classified as an Investor Presentation (IP) announcement or a general Regulatory Filing (RNS). Given the context of promoting scientific findings and company technology, and since it is an announcement *about* a presentation, it is closest to an Investor Presentation (IP) context, but since it's a press release format announcing participation in a third-party scientific meeting, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for non-standard corporate news releases that don't fit the other specific categories like ER or DIV. However, looking closely at the definitions, it is a news item about the company's technology being presented, which is often categorized under general news releases. RNS is the best fit for general corporate news that isn't a specific financial report or management change.
2022-06-13 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated June 13, 2022, announcing that Theraclion's technology (HIFU) was presented at the annual congress of the Society of Interventional Radiology (SIR) in Boston on June 15th. It details the content of the presentation and the context of the medical conference. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It is an announcement about company activity, specifically related to scientific/medical presentation and collaboration, which often falls under general investor relations or regulatory news. Since it is an announcement about scientific/medical findings being presented at a professional society meeting, and it doesn't fit the specific categories like AGM-R, ER, or IR, it is best classified as a general Regulatory Filing (RNS) as a broad announcement of corporate/scientific news, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is a press release *about* the presentation. Given the options, RNS serves as the best general regulatory/news announcement category for non-standard disclosures.
2022-06-13 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated May 16th, 2022, announcing the launch of a new product, SONOVEIN® HD, by the company THERACLION. It details the product features, quotes management and a key physician, and provides company background. This type of announcement, focusing on a significant business event (product launch) rather than mandatory periodic financial reporting (like 10-K or IR) or shareholder voting results, typically falls under general corporate news or regulatory announcements. Since there is no specific category for a 'Product Launch Announcement' and it is not a standard financial filing, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate announcements that are often filed with regulators or stock exchanges for public dissemination.
2022-05-16 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated May 16, 2022, announcing the launch of a new product, SONOVEIN® HD, by the company THERACLION. It details product features, quotes management and a key opinion leader, and provides company background. This type of announcement, focusing on a specific business event (product launch) rather than periodic financial results (ER, IR, 10-K) or management changes (MANG), typically falls under general regulatory announcements or news releases. Since there is no specific category for a 'Product Launch Announcement' and it is not a financial report, a call transcript, or a director dealing report, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous official announcements.
2022-05-16 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.